All In Biotech

Drug Trial Radar · NCT06767150

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Oct 2030

Study completion Oct 2030

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.

Conditions

  • Postmenopausal Osteoporosis

Interventions

  • a second infusion of ZOL when crosslaps levels reach 300 pg/mLDrug

    a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12

  • a rescue second infusion at month-12 (standard traitment)Drug

    a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintain lumbar bone mineral density (BMD) after 1 year of ZOLTime frame: 1 year after inclusion

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Amiens Hospital

    Amiens, France · Recruiting

  • Bordeaux Hospital

    Bordeaux, France · Recruiting

  • Cahors Hospital

    Cahors, France · Recruiting

  • Dax Hospital

    Dax, France · Recruiting

  • Le Mans Hospital

    Le Mans, France · Recruiting

  • Lille Hospital

    Lille, France · Not yet recruiting

  • Limoges Hospital

    Limoges, France · Recruiting

  • Marseille Hsopital

    Marseille, France · Recruiting

  • Montpellier Hospital

    Montpellier, France · Recruiting

  • Nice Hospital

    Nice, France · Recruiting

  • Orléans Hospital

    Orléans, France · Recruiting

  • Cochin Hospital

    Paris, France · Recruiting

  • Lariboisiere Hospital

    Paris, France · Recruiting

  • Poitiers Hospital

    Poitiers, France · Recruiting

  • Rennes Hospital

    Rennes, France · Recruiting

  • Saint Etienne Hospital

    Saint-Etienne, France · Recruiting

  • Toulouse Hospital

    Toulouse, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.